The journey of belantamab mafodotin in multiple myeloma
Host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD,
Host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD,
The US Food and Drug Administration has granted accelerated approval to linvoseltamab (Lynozyfic) in adults patients with relapsed or refractory multiple myeloma who
In this video interview, Anastasia Vasileva, MD, a researcher at the National Research Center for Hematology in Moscow, discusses findings from a study
Andrew Kuykendall, MD, assistant member in Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, discusses the phase 3 VERIFY trial primary results,
The US Food and Drug Administration (FDA) has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for all currently approved BCMA- and CD19-directed
Elias Jabbour, MD, and Naval Daver, MD, both of the University of Texas MD Anderson Cancer Center, discuss challenges in TP53-mutated acute myeloid
Rami Komrokji, MD, of Moffitt Cancer Center in Tampa, Florida, presented an update at the 2025 European Hematology Association Congress in Milan on
In this video interview, Guillermo Garcia-Manero, MD, chief of the section of myelodysplastic syndromes at the University of Texas MD Anderson Cancer Center,
The presence of certain intratumoral microbes was linked to survival outcomes in diffuse large B-cell lymphoma (DLBCL), according to findings presented at ICML
The combination of so-called “Boom Boom” radiotherapy prior to treatment with lisocabtagene maraleucel (liso-cel) was found to be safe, feasible, and effective, according